Zentalis Pharmaceuticals, a Phase 1/2 biotech developing novel small molecule therapies for various cancers, raised $165 million in an upsized IPO by offering 9.2 million shares at $18, the high end of the range of $16 to $18. The company originally planned to sell 7.7 million shares. Zentalis Pharmaceuticals plans to list on the Nasdaq under the symbol ZNTL. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as lead managers on the deal.
